Sanofi (SAN) Collaboration summary

Opening remarks and agenda

• Expanded a 20-year alliance focused on Type 2 inflammation medicines, building on a track record of collaboration and leadership in atopic dermatitis.

Alliance expansion and strategic objectives

• Expanded collaboration adds four next-generation, long-acting antibodies targeting IL-13, IL-4/IL-13, IL-4 receptor alpha, and IL-4, extending the alliance beyond DUPIXENT.

• The alliance aims to accelerate innovative therapies for immune-mediated diseases, using established development and global commercial platforms to reach patients.

Partner roles and collaborative capabilities

• Regeneron leads development decisions; Sanofi retains final commercial authority, including access and pricing, with Regeneron gaining greater participation in key payer engagements.

• Partners combine antibody discovery and immunology expertise with clinical experience, prescriber relationships, patient services, supply capabilities, and global market access.

• Programs will advance in parallel, with learnings shared across assets; experience from nine approved DUPIXENT indications may inform trial design and execution.